This week, an additional 29 companies have announced! TIGERMED and several other stocks disclosed repurchase and shareholding refinancing plans, with a list of related A-shares overview.
① The number of A-share listed companies receiving special loan support continues to expand. According to incomplete Statistics, as of the time of writing, 29 listed companies have disclosed information related to share repurchase and increased shareholding for re-loan this week (see attached table); ② TIGERMED received the highest amount of special loan support, totaling no more than 0.7 billion yuan.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
The Aimee vaccine / Baked Biological Type II Herpes Simplex Virus mRNA vaccine has been approved for clinical trials.
It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.
① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.
A total scale of 30 billion! The first national-level mother fund in the foreign trade and economic field is being raised, introducing listed company LP Jinbo Bio and Joinn Laboratories.
① The Innovation and Development Guidance Fund for Service Trade is a national-level fund initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, approved by the State Council, with a total scale of 30 billion yuan. ② An IR practitioner stated to the Star Daily that the second phase of the service trade fund inviting listed companies to become LPs may be a more market-oriented signal.